Linzagolix in moderate to severe symptoms of uterine fibroids: a profile of its use

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest S. Fung and H. A. Blair are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here.

Abstract 

Linzagolix (Yselty®) is an orally administered gonadotropin-releasing hormone receptor antagonist approved in the EU for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age and extends the treatment options in this indication. Linzagolix is available as different treatment regimens: for short-term use to reduce uterine and fibroid volumes; and for longer-term use to manage fibroid-associated symptoms. In two placebo-controlled phase 3 trials, linzagolix as a single agent or in combination with hormonal add-back therapy significantly reduced the proportion of patients with heavy menstrual bleeding, improved other symptoms associated with uterine fibroids (including anaemia and pain) and improved patient quality of life. Linzagolix was generally well tolerated, with hot flushes and headaches being the most common adverse events. 

© Springer Nature Switzerland AG 2023